Acute Tumor Inflammation with CD4/8+ and CD11+ Prolong The Survival Effect Induced by Intratumral Injection Optimum Combination of Chemotherapy Drugs with Hydralazine as Hapten in Animal Model

肼氮嗪 炎症 化疗 医学 半抗原 药理学 动物模型 癌症研究 免疫学 内科学 抗体 血压
作者
Baofa Yu,Qiang Fu,Yaling Han,Dong Chen
出处
期刊:Japanese Journal of Gastroenterology and Hepatology 卷期号:08 (17)
标识
DOI:10.47829/jjgh.2022.81701
摘要

Purpose: To study the survival time of mice with tumor by intratumoral injection with chemotherapy drug Adr plus hapten of DNP or Hydra and find a combination of drugs of Adr with DNP or Hydra can prolong their life, and which one of DNP or Hydra can provide a long life extension of mice with tumor. Method: After inoculation of tumor cells into mice, tumor reach at 4~5mm size as the experiment day 0, the random groups was performed for intratumoral injection with corresponding drugs combination of Adr+DNP or Hydra and Adr or ARA-C control group, follow up to 90 days to find which combination of drugs could provide a longer their life extension of mice with tumor. Result: Comparison the body weight between the groups, there is not significantly different but the control group maintains the stable of weight. it indicated that PYM could not alone induce a expression of immunity at all and DNP as hapten is playing an important role in stimulation of immunity reaction. There is a significant difference between the tumor volume in treatment group and control group from day1 to day 41, it showed that local injection of combination drug can control tumor growth in the difference drugs group. There is a significant difference between survival time in treatment group and the control group. The life extension rate is 31.4% for group of A1 (Adr+Hydra I) is bigger than A2 (Adr+Hydra II) which has same formulation with high dose of Hydra, and A3 (Adr+Ara-C+Hydra) which has one more drug of Ara-CA2; life extension rate for B group, B1 (Adr+DNP) is 24.4%, it is bigger than B2 (Adr+Ara-C+DNP) which has one more drug of Ara-C; Both of A1 and B1 is better than D (Adr+Ara-C) in the life extension rate, it indicated that best Hydra dose in A1 and DNP in B1 played an important role in the life extension, Hydra is a better hapten than DNP. Conclusion: It has further confirmed the abscopal effect induced by chemotherapy drug Adr plus DNP or Hydra is optimum combination with compatibility and could prolong their life of mice, it offer a novel eclectic approach for treating cancer through the Hydra modify with TAA in vivo with intratumoral injection best combination with chemotherapy drug.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稳重傲儿完成签到 ,获得积分10
2秒前
喜悦的月光完成签到,获得积分10
2秒前
shierfang完成签到 ,获得积分10
4秒前
想飞的熊完成签到 ,获得积分0
7秒前
xwl9955完成签到 ,获得积分10
13秒前
18秒前
小趴菜完成签到 ,获得积分10
22秒前
陈秋发布了新的文献求助10
24秒前
没用的三轮完成签到,获得积分10
26秒前
kk完成签到 ,获得积分10
34秒前
logolush完成签到 ,获得积分10
39秒前
42秒前
海孩子完成签到,获得积分10
44秒前
Yolenders完成签到 ,获得积分10
45秒前
仓促过客发布了新的文献求助10
46秒前
朴素海亦完成签到 ,获得积分10
53秒前
Xie完成签到 ,获得积分10
58秒前
金生六完成签到 ,获得积分0
1分钟前
南岸娜娜完成签到 ,获得积分10
1分钟前
...完成签到 ,获得积分10
1分钟前
王磊完成签到 ,获得积分10
1分钟前
changfox完成签到,获得积分10
1分钟前
ran完成签到 ,获得积分10
1分钟前
richard1357完成签到 ,获得积分10
1分钟前
老王完成签到 ,获得积分10
1分钟前
S.S.N完成签到 ,获得积分10
1分钟前
wang发布了新的文献求助10
1分钟前
我独舞完成签到 ,获得积分10
2分钟前
六等于三二一完成签到 ,获得积分10
2分钟前
嘿嘿完成签到 ,获得积分10
2分钟前
twelveyears完成签到 ,获得积分10
2分钟前
酸番茄完成签到 ,获得积分10
2分钟前
isedu完成签到,获得积分10
2分钟前
小杨完成签到 ,获得积分10
2分钟前
斯文败类应助科研通管家采纳,获得10
2分钟前
zjuszk完成签到 ,获得积分10
2分钟前
小马甲应助adeno采纳,获得10
2分钟前
闪闪的谷梦完成签到 ,获得积分10
2分钟前
suyou完成签到 ,获得积分10
2分钟前
细心的语蓉完成签到,获得积分10
2分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Essentials of thematic analysis 700
A Dissection Guide & Atlas to the Rabbit 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3126186
求助须知:如何正确求助?哪些是违规求助? 2776349
关于积分的说明 7729904
捐赠科研通 2431800
什么是DOI,文献DOI怎么找? 1292298
科研通“疑难数据库(出版商)”最低求助积分说明 622696
版权声明 600430